Abstract 1712P
Background
Schlafen-11 (SLFN-11) was recently identified as a predictive marker of platinum-based drugs. In Japan, neoadjuvant chemotherapy, consists of 5-fluorouracil and cisplatin (NAC-FP), followed by surgery is the standard therapy for patients (pts) with resectable esophageal squamous cell carcinoma (ESCC). However, the correlation between SLFN-11 expression level and prognosis in ESCC pts treated with NAC-FP is unclear.
Methods
We retrospectively evaluated pts with ESCC who received NAC-FP between January 2009 and December 2019. Formalin-fixed paraffin-embedded specimen of ESCC were subjected to immunohistochemical staining with an anti-SLFN-11 mouse monoclonal antibody (Santa Cruz Biotech, USA). The SLFN-11 expression level was evaluated by using a semi-quantitative method, calculated each of the histo-score (H-score), and divided into SLFN-11 positive group (P) and negative group (N). H-score≥1 was defined as P. Disease-free survival (DFS), overall survival (OS) with each 95% confidence interval (CI) were estimated by Kaplan-Meier method. Differences between each group were tested by the log-rank test. The Cox regression analysis was used to estimate hazard ratio (HR).
Results
The total of 40 pts were analyzed. Median age (range); 66 (38-79), male/female; 31/9, cStage II/III; 18/22, median H-score (range); 35 (0-255), P/N; 31/8 (one was absent of tumor), respectively. The median follow-up was 62.1 months (range: 4.7-156.2). 3-year DFS rate was 57.0% in P, 0.0% in N, respectively (HR 0.43 [95%CI: 0.16-1.14], p=0.07). 3-year OS rate was 71.0% in P, 14.6% in N, respectively (HR 0.22 [95%CI: 0.08-0.57], p<0.01). According to cstage II, 3-year DFS rate was 85.7% vs 0.0%, respectively (HR 0.16 [95%CI: 0.02-1.03], p=0.03). 3-year OS rate was 85.7% vs 26.7%, respectively (HR 0.09 [95%CI: 0.02-0.52], p<0.01).
Conclusions
It was estimated that the SLFN-11 expression level could be useful as one of the possible predictive and prognostic markers in ESCC.
Clinical trial identification
020-0417.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.